Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
NICE is poised to deliver key commitments in the government’s 10 Year Plan for health and care. We’re delighted by the plan’s endorsement of our role in delivering faster, and fairer access to the best innovations. It will strengthen our position in the system, guided by our core purpose.
Our annual report and accounts summarise our key achievements from April 2024 to March 2025.
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
